News

Smith highlights advances in interventional glaucoma, including first-line SLT, emerging surgical options, and co-management strategies, during the Ophthalmology Times and Optometry Times EyeCon 2025 conference.

This new technology, the MacuMira system, is a non-invasive treatment now available in more than 150 clinics across Canada.

Residents across ophthalmology, optometry, and retina care were recognized for leadership, research, and dedication to advancing patient care.

Broadwood Partners, who is against the merger, holds approximately 27.5% of the outstanding common stock of STAAR, making them the largest outside stockholder of STAAR.

Considering rapid increases in myopia, authors conducted a longitudinal cohort study of twins and their parents with the goal of exploring the intergenerational changes in the myopia epidemic in China.

A study reveals that repetitive head impacts in college football players do not significantly affect smooth pursuit eye movement velocity during a season.

In honor of looking back at 50 years, we look forward at a world where the toughest eye diseases could be cured in the blink of an eye.

Canadian researchers reveal increased complications in cataract surgeries during the COVID-19 pandemic, highlighting risks and factors affecting outcomes.

Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and is the generic equivalent of LUMIGAN.

EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.

The window shop provision in the Alcon merger agreement enabled STAAR to accept a competing acquisition proposal and terminate the Alcon merger.

Conavi leverages ophthalmic imaging technology to enhance intravascular diagnostics in cardiology.

The partnership was announced in August of this year.

OKYO Pharma advances urcosimod for neuropathic corneal pain, targeting a new clinical trial to optimize treatment and registration pathways.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research, networking opportunities, and empowering women in retina.

Potential loss to follow-up is a critical issue for these patients with glaucoma.

Discover new insights into central serous chorioretinopathy, including pathophysiology, imaging techniques, and effective treatment options for better patient outcomes.

Character Biosciences enhances its leadership team and secures $93 million in Series B funding to advance treatments for degenerative eye diseases.

Guymer discusses early intervention strategies for intermediate AMD, highlighting risk factors, and potential trial designs to prevent vision loss.

IVMED-85 is a preservative-free prescription eye drop designed to prevent myopia progression in children.

We ask leading experts in the field what eye disease they would cure and why.

A new staging system for diabetic retinopathy and macular edema is essential, integrating advanced imaging techniques for better disease management and patient outcomes.